---
title: "Life Saving Drug Combination Could Prevent Second Heart Attack Study Shows"
publisher: "Stockmark.IT"
author: "Stockmark.IT Website"
published: "2025-04-16T07:06:30+00:00"
modified: "2025-04-16T07:06:30+00:00"
date: 2025-04-16
canonical: "https://stockmark.it/life-saving-drug-combination-could-prevent-second-heart-attack-study-shows/"
category: "Health"
categories: ["Health", "Healthcare", "Medical Research", "Medical Science", "NHS", "Pharmaceutical"]
image: "https://i0.wp.com/stockmark.it/wp-content/uploads/1744725014759_XVJXL8JW.jpg?fit=1024%2C576&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Life Saving Drug Combination Could Prevent Second Heart Attack Study Shows

**Published:** April 16, 2025
**Author:** Stockmark.IT Website
**Categories:** Health, Healthcare, Medical Research, Medical Science, NHS, Pharmaceutical
**Featured image:** ![heart health through drug combination discovery](https://i0.wp.com/stockmark.it/wp-content/uploads/1744725014759_XVJXL8JW.jpg?fit=1024%2C576&quality=89&ssl=1)

---

Research suggests that thousands of lives could be saved and subsequent heart attacks or strokes prevented through the administration of two cost-effective medicines. The study, conducted jointly by Imperial College London and Lund University in Sweden, demonstrates significant promise in reducing cardiovascular events.

The research analysed data from 36,000 Swedish patients who experienced heart attacks between 2015 and 2022. The findings revealed that patients receiving a combination of statins and ezetimibe within 12 weeks of their initial heart attack displayed markedly improved outcomes compared to those who received delayed treatment or statins alone.

Professor Kausik Ray from Imperial’s School of Public Health emphasises the economic viability of this treatment protocol, noting the annual cost per patient at approximately £350. This expenditure represents substantial value when measured against the comprehensive costs of treating subsequent cardiac events and their impact on patients’ quality of life.

The timing of treatment administration proves crucial, as the first year following a heart attack presents the highest risk for subsequent events. Blood vessels remain particularly susceptible during this period, increasing the likelihood of blood clot formation. The dual-drug approach effectively addresses this vulnerability.

Despite ezetimibe’s widespread availability and modest cost, current global treatment guidelines have not universally adopted this combination therapy. Dr Margret Leosdottir, associate professor at Lund University, attributes this hesitation to an overly cautious approach regarding potential side effects and overmedication concerns.

The research findings present a compelling case for immediate revision of international treatment protocols. The demonstrated efficacy, coupled with the medication’s favourable side effect profile and accessibility, positions this combination therapy as a potentially transformative approach in post-heart attack care management.

---

**Original URL:** https://stockmark.it/life-saving-drug-combination-could-prevent-second-heart-attack-study-shows/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*